The influence of gut microbiota on drug metabolism and toxicity

Bibliography

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers

• Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312(5778):1355–1359.
   PubMed Web of Science ®Google Scholar
• Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65.
   PubMed Web of Science ®Google Scholar
• Jia W, Li H, Zhao L, et al. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov. 2008;7(2):123–129.
   PubMed Web of Science ®Google Scholar

•This review provides an overview of gut microbiota involvement in disease development and hypothesizes that gut microbiota could be a potential drug target.

• Kang MJ, Kim HG, Kim JS, et al. The effect of gut microbiota on drug metabolism. Expert Opin Drug Metab Toxicol. 2013;9(10):1295–1308.
   PubMed Web of Science ®Google Scholar

••This review systemically summarized the gut microbiota modulation on many natural products and synthetic drugs.

• Rajilic-Stojanovic M, Smidt H, De Vos WM. Diversity of the human gastrointestinal tract microbiota revisited. Environ Microbiol. 2007;9(9):2125–2136.
   PubMed Web of Science ®Google Scholar
• Saad R, Rizkallah MR, Aziz RK. Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes. Gut Pathog. 2012;4(1):16.
   PubMed Web of Science ®Google Scholar

•This paper discussed the complicated relationship between host and gut microbes, and coined the term of “pharmacomicrobiomics”.

• Haiser HJ, Turnbaugh PJ. Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013;69(1):21–31.
   PubMed Web of Science ®Google Scholar

••In this paper, the authors summarized the roles of gut microbiota in xenobiotic metabolism with some important examples.

• Clayton TA, Baker D, Lindon JC, et al. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA. 2009;106(34):14728–14733.
   PubMed Web of Science ®Google Scholar
• Haiser HJ, Gootenberg DB, Chatman K, et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science. 2013;341(6143):295–298.
   PubMed Web of Science ®Google Scholar
• Westman EL, Canova MJ, Radhi IJ, et al. Bacterial inactivation of the anticancer drug doxorubicin. Chem Biol. 2012;19(10):1255–1264.
   PubMed Web of Science ®Google Scholar
• Lindenbaum J, Rund DG, Butler VP Jr., et al. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med. 1981;305(14):789–794.
   PubMed Web of Science ®Google Scholar
• Goldin BR, Peppercorn MA, Goldman P. Contributions of host and intestinal microflora in the metabolism of L-dopa by the rat. J Pharmacol Exp Ther. 1973;186(1):160–166.
   PubMed Web of Science ®Google Scholar
• Koch RL, Goldman P. The anaerobic metabolism of metronidazole forms N-(2-hydroxyethyl)-oxamic acid. J Pharmacol Exp Ther. 1979;208(3):406–410.
   PubMed Web of Science ®Google Scholar
• Aura AM, Mattila I, Hyotylainen T, et al. Drug metabolome of the simvastatin formed by human intestinal microbiota in vitro. Mol Biosyst. 2011;7(2):437–446.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Kim IS, Van Le TK, et al. Gut microbiota-mediated drug interactions between lovastatin and antibiotics. Drug Metab Dispos. 2014;42(9):1508–1513.
   PubMed Web of Science ®Google Scholar

•This paper provides evidence for gut microbial impacts on drug metabolism, such as for lovastatin.

• Mikov M, Caldwell J, Dolphin CT, et al. The role of intestinal microflora in the formation of the methylthio adduct metabolites of paracetamol. Studies in neomycin-pretreated and germ-free mice. Biochem Pharmacol. 1988;37(8):1445–1449.
   PubMed Web of Science ®Google Scholar
• Shu YZ, Kingston DG, Van Tassell RL, et al. Metabolism of levamisole, an anti-colon cancer drug, by human intestinal bacteria. Xenobiotica. 1991;21(6):737–750.
   PubMed Web of Science ®Google Scholar
• Jin MJ, Kim U, Kim IS, et al. Effects of gut microflora on pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-free rats. J Toxicol Environ Health A. 2010;73(21–22):1441–1450.
   PubMed Web of Science ®Google Scholar
• Lee NK, Choi SH, Park SH, et al. Antiallergic activity of hesperidin is activated by intestinal microflora. Pharmacology. 2004;71(4):174–180.
   PubMed Web of Science ®Google Scholar
• Caldwell J, Hawksworth GM. The demethylation of methamphetamine by intestinal microflora. J Pharm Pharmacol. 1973;25(5):422–424.
   PubMed Web of Science ®Google Scholar
• Basit AW, Newton JM, Lacey LF. Susceptibility of the H2-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora. Int J Pharm. 2002;237(1–2):23–33.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Yamashita S, Furuno K, et al. Metabolism of omeprazole by gut flora in rats. J Pharm Sci. 1995;84(4):516–517.
   PubMed Web of Science ®Google Scholar
• Meuldermans W, Hendrickx J, Mannens G, et al. The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab Dispos. 1994;22(1):129–138.
   PubMed Web of Science ®Google Scholar
• Wadworth AN, Olsalazine FA. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs. 1991;41(4):647–664.
   PubMed Web of Science ®Google Scholar
• Strong HA, Renwick AG, George CF, et al. The reduction of sulphinpyrazone and sulindac by intestinal bacteria. Xenobiotica. 1987;17(6):685–696.
   PubMed Web of Science ®Google Scholar
• Holt R. The bacterial degradation of chloramphenicol. Lancet. 1967;1(7502):1259–1260.
   PubMed Web of Science ®Google Scholar
• Tozaki H, Emi Y, Horisaka E, et al. Metabolism of peptide drugs by the microorganisms in rat cecal contents. Biol Pharm Bull. 1995;18(6):929–931.
   PubMed Web of Science ®Google Scholar
• Shim SB, Kim NJ, Kim DH. Beta-glucuronidase inhibitory activity and hepatoprotective effect of 18 beta-glycyrrhetinic acid from the rhizomes of Glycyrrhiza uralensis. Planta Med. 2000;66(1):40–43.
   PubMed Web of Science ®Google Scholar
• Akao T, Hayashi T, Kobashi K, et al. Intestinal bacterial hydrolysis is indispensable to absorption of 18-beta-glycyrrhetic acid after oral-administration of glycyrrhizin in rats. J Pharm And Pharmacol. 1994;46(2):135–137.
   PubMed Web of Science ®Google Scholar
• Takeno S, Sakai T. Involvement of the intestinal microflora in nitrazepam-induced teratogenicity in rats and its relationship to nitroreduction. Teratology. 1991;44(2):209–214.
   PubMedGoogle Scholar
• Harris BE, Manning BW, Federle TW, et al. Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora. Antimicrob Agents Chemother. 1986;29(1):44–48.
   PubMed Web of Science ®Google Scholar
• Lavrijsen K, Van Dyck D, Van Houdt J, et al. Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans. Drug Metab Dispos. 1995;23(3):354–362.
   PubMed Web of Science ®Google Scholar
• Tralau T, Sowada J, Luch A. Insights on the human microbiome and its xenobiotic metabolism: what is known about its effects on human physiology? Expert Opin Drug Metab Toxicol. 2015;11(3):411–425.
   PubMed Web of Science ®Google Scholar
• Li H, Jia W. Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity. Clin Pharmacol Ther. 2013;94(5):574–581.
   PubMed Web of Science ®Google Scholar

••This review discussed the cometabolism between host and microbiota, and summarized the drugs metabolized by gut microbiota.

• Nakayama H, Kinouchi T, Kataoka K, et al. Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Pharmacogenetics. 1997;7(1):35–43.
   PubMedGoogle Scholar
• Mao B, Li D, Zhao J, et al. In vitro fermentation of lactulose by human gut bacteria. J Agric Food Chem. 2014;62(45):10970–10977.
   PubMed Web of Science ®Google Scholar
• Sahota SS, Bramley PM, Menzies IS. The fermentation of lactulose by colonic bacteria. J Gen Microbiol. 1982;128(2):319–325.
   PubMedGoogle Scholar
• Trinh HT, Joh EH, Kwak HY, et al. Anti-pruritic effect of baicalin and its metabolites, baicalein and oroxylin A, in mice. Acta Pharmacol Sin. 2010;31(6):718–724.
   PubMed Web of Science ®Google Scholar
• Kang MJ, Ko GS, Oh Do G, et al. Role of metabolism by intestinal microbiota in pharmacokinetics of oral baicalin. Arch Pharm Res. 2014;37(3):371–378.
   PubMed Web of Science ®Google Scholar
• Matthies A, Clavel T, Gutschow M, et al. Conversion of daidzein and genistein by an anaerobic bacterium newly isolated from the mouse intestine. Appl Environ Microbiol. 2008;74(15):4847–4852.
   PubMed Web of Science ®Google Scholar
• Renouf M, Hendrich S. Bacteroides uniformis is a putative bacterial species associated with the degradation of the isoflavone genistein in human feces. J Nutr. 2011;141(6):1120–1126.
   PubMed Web of Science ®Google Scholar
• Akao T, Kida H, Kanaoka M, et al. Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb-1 from Panax ginseng. J Pharm And Pharmacol. 1998;50(10):1155–1160.
   PubMed Web of Science ®Google Scholar
• Matthies A, Loh G, Blaut M, et al. Daidzein and genistein are converted to equol and 5-hydroxy-equol by human intestinal Slackia isoflavoniconvertens in gnotobiotic rats. J Nutr. 2012;142(1):40–46.
   PubMed Web of Science ®Google Scholar
• Schneider H, Simmering R, Hartmann L, et al. Degradation of quercetin-3-glucoside in gnotobiotic rats associated with human intestinal bacteria. J Appl Microbiol. 2000;89(6):1027–1037.
   PubMed Web of Science ®Google Scholar
• Di L. The role of drug metabolizing enzymes in clearance. Expert Opin Drug Metab Toxicol. 2014;10(3):379–393.
   PubMed Web of Science ®Google Scholar
• Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet. 2012;13(4):260–270.
   PubMed Web of Science ®Google Scholar
• Davidson DG, Eastham WN. Acute liver necrosis following overdose of paracetamol. Br Med J. 1966;2(5512):497–499.
   PubMed Web of Science ®Google Scholar
• Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364–1372.
   PubMed Web of Science ®Google Scholar
• Smith EA, Macfarlane GT. Formation of phenolic and indolic compounds by anaerobic bacteria in the human large intestine. Microb Ecol. 1997;33(3):180–188.
   PubMed Web of Science ®Google Scholar
• Lee SH, An JH, Lee HJ, et al. Evaluation of pharmacokinetic differences of acetaminophen in pseudo germ-free rats. Biopharm Drug Dispos. 2012;33(6):292–303.
   PubMed Web of Science ®Google Scholar
• Gamage N, Barnett A, Hempel N, et al. Human sulfotransferases and their role in chemical metabolism. Toxicol Sci. 2006;90(1):5–22.
   PubMed Web of Science ®Google Scholar
• Possamai LA, McPhail MJ, Khamri W, et al. The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity. Liver Int. 2015;35(3):764–773.
   PubMed Web of Science ®Google Scholar
• Jacobs WAHA. The relationship between the structure and the biological action of the cardiac glucosides. J Biol Chem. 1927;74:787–793.
   Google Scholar
• Vick RL KJJ, Acheson GH. Effects of dihydroouabain, dihydrodigoxin and dihydrodigitoxin on the heart-lung preparation of the dog. J Pharmacol Exp Ther. 1957;121:330–339.
   PubMed Web of Science ®Google Scholar
• Saha JR, Butler VP Jr., Neu HC, et al. Digoxin-inactivating bacteria: identification in human gut flora. Science. 1983;220(4594):325–327.
   PubMed Web of Science ®Google Scholar
• Wilson ID. Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring. Proc Natl Acad Sci USA. 2009;106(34):14187–14188.
   PubMed Web of Science ®Google Scholar
• Kajinami K, Akao H, Polisecki E, et al. Pharmacogenomics of statin responsiveness. Am J Cardiol. 2005;96(9A):65K–70K. discussion 34K–35K.
   Web of Science ®Google Scholar
• Charlab R, Zhang L. Pharmacogenomics: historical perspective and current status. Methods Mol Biol. 2013;1015:3–22.
   PubMedGoogle Scholar
• Yip LY, Chan EC. Investigation of host-gut microbiota modulation of therapeutic outcome. Drug Metab Dispos. 2015;43(10):1619–1631.
   PubMedGoogle Scholar
• Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336(6086):1268–1273.
   PubMed Web of Science ®Google Scholar
• Sistigu A, Viaud S, Chaput N, et al. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol. 2011;33(4):369–383.
   PubMed Web of Science ®Google Scholar
• Schiavoni G, Sistigu A, Valentini M, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 2011;71(3):768–778.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004;34(2):336–344.
   PubMed Web of Science ®Google Scholar
• Viaud S, Flament C, Zoubir M, et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res. 2011;71(3):661–665.
   PubMed Web of Science ®Google Scholar
• Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971–976.
   PubMed Web of Science ®Google Scholar

•This paper provides evidence for gut microbial impacts on drug efficacy such as with cyclophosphamide.

• Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967–970.
   PubMed Web of Science ®Google Scholar
• Vanhoefer U, Harstrick A, Achterrath W, et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol. 2001;19(5):1501–1518.
   PubMed Web of Science ®Google Scholar
• Stringer AM, Gibson RJ, Logan RM, et al. Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther. 2008;7(12):1919–1925.
   PubMed Web of Science ®Google Scholar
• Takasuna K, Hagiwara T, Hirohashi M, et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 1996;56(16):3752–3757.
   PubMed Web of Science ®Google Scholar
• Wallace BD, Wang H, Lane KT, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 2010;330(6005):831–835.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239.
   PubMed Web of Science ®Google Scholar
• Barber MJ, Mangravite LM, Hyde CL, et al. Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One. 2010;5(3):e9763.
   PubMed Web of Science ®Google Scholar
• Kaddurah-Daouk R, Baillie RA, Zhu H, et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS One. 2011;6(10):e25482.
   PubMed Web of Science ®Google Scholar
• Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012;21(4):504–516.
   PubMed Web of Science ®Google Scholar
• Wikoff WR, Anfora AT, Liu J, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA. 2009;106(10):3698–3703.
   PubMed Web of Science ®Google Scholar
• Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012;336(6086):1262–1267.
   PubMed Web of Science ®Google Scholar

•This review discussed the intricate relationship between host and gut microbiota.